Ovid Therapeutics shares surge 21.07% after-hours as analysts upgrade or maintain Buy ratings with $4 price targets.

Ovid Therapeutics surged 21.07% in after-hours trading following renewed analyst optimism. H.C. Wainwright’s Ram Selvaraju reiterated a Buy rating, citing positive KCC2 platform progress, while LifeSci Capital maintained a Buy rating with a $4 price target and separately initiated coverage with an Outperform rating at the same target. The consecutive bullish analyst actions highlighted confidence in Ovid’s therapeutic pipeline advancements, directly aligning with the sharp post-market price increase.